Overexpression of EGFR plays a key role in HNSCC, supporting the use of cetuximab, a monoclonal anti‐EGFR antibody, as well as EGFR‐tyrosine kinase inhibitors (EGFR‐TKI), which inhibit tumor cell proliferation and the secretion of pro‐angiogenic factors by tumor cells, such as VEGF and IL‐8. Here, VEGFA is linked to neoplasm.